BioNTech Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

BioNTech hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$0.47
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

Mar 05

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Feb 18

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von BNTX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von BNTX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

BioNTech Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von BNTX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (BNTX)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (BNTX)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von BNTX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von BNTX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von BNTX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da BNTX keine Ausschüttungen gemeldet hat.

BioNTech Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to €1.74 loss

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioNTech Earnings Preview: I Will Stay On The Sidelines

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

Independent Supervisory Board Chairman notifies of intention to sell stock

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Consensus EPS estimates fall by 15%

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 10%

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Investor sentiment deteriorated over the past week

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations